Filippos Anagnostakis

Dr. Filippos Anagnostakis

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Nature Aging
Verified
Journal Article
Closed access
PDF file
JWJunhao Wen
Junhao Wen
YTYe Ella Tian
Ye Ella Tian
ISIoanna Skampardoni
Ioanna Skampardoni
ZYZhijian Yang
Zhijian Yang
YCYuhan Cui
Yuhan Cui
CDChristos Davatzikos
Christos Davatzikos

26 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCThe MULTI consortium
The MULTI consortium
AZAndrew Zalesky
Andrew Zalesky
YTYe Ella Tian
Ye Ella Tian
LFLuigi Ferrucci
Luigi Ferrucci
KWKeenan A. Walker
Keenan A. Walker
JWJunhao Wen
Junhao Wen
Multi-organ biological aging clocks across different organ systems have been shown to predict human disease and mortality. Here, we extend this multi-organ framework to plasma metabolomics, developing five organ-specific metabolome-based biological age gaps (MetBAGs) using 107 plasma non-derivatized metabolites from 274,247 UK Biobank participants. Our age prediction models achieve a mean absolute error of approximately 6 years (0.25<r < 0.42). Crucially, including composite metabolites (e.g. sums or ratios of raw metabolites) results in poor generalizability to independent test data due to multicollinearity. Genome-wide associations identify 405 MetBAG-locus pairs (P < 5 × 10−8/5). Using SBayesS, we estimate the SNP-based heritability (0.09<\({h}_{{SNP}}^{2}\) < 0.18), negative selection signatures (−0.93 < S < −0.76), and polygenicity (0.001<Pi < 0.003) for the 5 MetBAGs. Genetic correlation and Mendelian randomization analyses reveal potential causal links between the 5 MetBAGs and cardiometabolic conditions (e.g., metabolic disorders and hypertension). Integrating multi-organ and multi-omics features improves disease category and mortality predictions. The 5 MetBAGs extend existing biological aging clocks to study human aging and disease across multiple biological scales. All results are publicly available at https://labs-laboratory.com/medicine/.

Verified
Journal Article
Open access
PDF file
FAFilippos Anagnostakis
Filippos Anagnostakis
MKMichail Kokkorakis
Michail Kokkorakis
MMMarkouli Mariam
Markouli Mariam
Christina PiperiChristina Piperi
Christina Piperi
Solute carriers (SLCs) are essential for brain physiology and homeostasis due to their role in transporting necessary substances across cell membranes. There is an increasing need to further unravel their pathophysiological implications since they have been proposed to play a pivotal role in brain tumor development, progression, and the formation of the tumor microenvironment (TME) through the upregulation and downregulation of various amino acid transporters. Due to their implication in malignancy and tumor progression, SLCs are currently positioned at the center of novel pharmacological targeting strategies and drug development. In this review, we discuss the key structural and functional characteristics of the main SLC family members involved in glioma pathogenesis, along with their potential targeting options to provide new opportunities for CNS drug design and more effective glioma management.

27 May 2025 in EBioMedicine
Verified
Journal Article
Open access
FAFilippos Anagnostakis
Filippos Anagnostakis
MKMichail Kokkorakis
Michail Kokkorakis
KWKeenan A. Walker
Keenan A. Walker
ISIoanna Skampardoni
Ioanna Skampardoni
JWJunhao Wen
Junhao Wen
CDChristos Davatzikos
Christos Davatzikos
The impact of high body mass index (BMI) states and associated proteomic factors on brain ageing and Alzheimer's disease (AD) remains unclear. We sought to evaluate machine learning (ML)-based neuroimaging markers of brain age and AD-like brain atrophy in participants with obesity or overweight without diagnosed cognitive impairment (WODCI), in a harmonised study of 46,288 participants in 15 studies (the Imaging-Based Coordinate System for Aging and Neurodegenerative Diseases (iSTAGING) consortium). We also assessed the association between cognition, serum proteins, and brain ageing indices. Data were acquired between 1999 and 2020 and analysed from November 2024 onwards. The study comprised 46,288 participants, including 24,897 females and 21,391 males, with a mean age of 64.33 years (SD = 8.13) and a mean BMI of 26.81 kg/m2 (SD = 4.49). The results demonstrate that the impact of obesity on brain ageing, and AD-like brain atrophy is weaker with increasing age and is significantly pronounced in males compared to females. Additionally, in males, obesity was significantly associated with approximately 2 additional years of brain ageing compared to normal weight and 1 additional year compared to the overweight group. Males with overweight also showed higher brain ageing values (8 additional months) than males with normal weight. Regarding AD-like brain atrophy, males with obesity displayed higher AD-like brain atrophy than males with normal weight, but females with normal weight showed higher AD-like brain atrophy than females with overweight. Sex differences within the same BMI categories were observed, with males exhibiting increased brain ageing compared to females, in obesity (1 additional year) and overweight groups (3 additional months). Higher AD-like brain atrophy was observed in males with overweight than in females with overweight. Females with normal weight displayed increased brain ageing (8 additional months) and AD-like brain atrophy relative to males with normal weight. In both retrospective and cross-sectional proteomics studies, five and eight proteins out of 1463 proteins were significantly (positively or negatively) associated with brain ageing and 1-SD BMI change (SD = 4.2 kg/m2), respectively. The findings demonstrate that higher BMI states are associated with accelerated brain ageing and AD-like atrophy, particularly in males, while females with normal weight demonstrated higher brain ageing and AD-like atrophy than males with normal weight. Moreover, the impact of obesity on brain ageing and AD-like brain atrophy becomes weaker with increasing age. Further research is needed to investigate sex-specific mechanisms by which weight gain influences brain ageing. National Institute on Aging's Intramural Research Program, National Institute on Aging, Intramural Research Program.

13 February 2026 in Endocrine Practice
Verified
Journal Article
Open access
FAFilippos Anagnostakis
Filippos Anagnostakis
MKMichail Kokkorakis
Michail Kokkorakis
To assess the long-term association between SARS-CoV-2 infection and the incidence of prediabetes and type 2 diabetes over a five-year period. We conducted a nationwide, population-based cohort study including adults who had a positive COVID-19 test (599,744) and adults with a negative COVID-19 test (4,485,145) between January 1, 2020, and December 31, 2020. Participants did not have a history of prior SARS-CoV-2 infection, diagnosis of prediabetes or type 2 diabetes, and were followed for 5 years. Propensity score matching was used to control confounding, and time-to-event analyses were performed using Kaplan-Meier analysis and Cox proportional hazards models. Among 5,084,889 individuals followed for a median of 2.6 years, those with confirmed SARS-CoV-2 infection exhibited a significantly increased risk of developing prediabetes (HR 1.23; 95% CI, 1.21-1.25) and type 2 diabetes (HR 1.40; 95% CI, 1.37-1.43) compared to uninfected individuals. The risk was most pronounced within the first month following infection (prediabetes: HR 1.87; 95% CI, 1.75-1.98; type 2 diabetes: HR 1.87; 95% CI, 1.79-1.96) and, although attenuated, remained significantly elevated over the subsequent five years (prediabetes: HR 1.23; 95% CI, 1.20-1.27; type 2 diabetes: HR 1.48; 95% CI, 1.43-1.53). SARS-CoV-2 infection is associated with a significantly increased risk of developing prediabetes and type 2 diabetes, with the highest incidence observed during the acute post-infection phase and persistent elevation in risk extending up to five years.

15 September 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
FAFilippos Anagnostakis
Filippos Anagnostakis
MKMichail Kokkorakis
Michail Kokkorakis
CAChristos Asvestis
Christos Asvestis
IPIlias Papadimopoulos
Ilias Papadimopoulos
SNShrihari Nagarajan
Shrihari Nagarajan
CDChristos Davatzikos
Christos Davatzikos
INTRODUCTION: This study investigates the impact of cardiometabolic conditions, including type 2 diabetes, hyperlipidemia, hypertension, and obesity, on the progression of mild cognitive impairment (MCI) to dementia. METHODS: The cohort included adults ≥ 50 years old with MCI and a cardiometabolic condition identified through electronic health records. Propensity score matching was applied to control for confounders, and Kaplan–Meier analysis was used to assess time‐to‐event outcomes. RESULTS: During a 7‐year median follow‐up, type 2 diabetes was associated with the highest risk of all‐cause dementia (hazard ratio [HR] 1.18, 95% confidence interval [CI]: 1.06 to 1.31), followed by hypertension and hyperlipidemia. For vascular dementia, type 2 diabetes conferred the greatest risk (HR 1.33, 95% CI: 1.07 to 1.64). Hyperlipidemia was the sole cardiometabolic factor significantly associated with Alzheimer's disease (AD) risk (HR 1.21, 95% CI: 1.11 to 1.32). CONCLUSIONS: Hyperlipidemia is primarily associated with AD dementia risk, while type 2 diabetes is the major contributor to vascular dementia and all‐cause risk in individuals with MCI. Highlights: Type 2 diabetes, hypertension, and hyperlipidemia are associated with a high risk of developing all‐cause dementia in participants already diagnosed with mild cognitive impairment (MCI). Type 2 diabetes was shown to pose a high risk for the progression from MCI to vascular dementia. Hyperlipidemia was associated with Alzheimer's disease progression in individuals with MCI.